Black Diamond Financial LLC Has $270,000 Holdings in Danaher Co. (NYSE:DHR)

Black Diamond Financial LLC cut its holdings in Danaher Co. (NYSE:DHR) by 12.7% during the third quarter, Holdings Channel.com reports. The firm owned 972 shares of the conglomerate’s stock after selling 142 shares during the quarter. Black Diamond Financial LLC’s holdings in Danaher were worth $270,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. nVerses Capital LLC acquired a new stake in shares of Danaher in the second quarter valued at approximately $25,000. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher during the second quarter worth $25,000. MFA Wealth Advisors LLC acquired a new position in Danaher during the second quarter worth $51,000. Financial Connections Group Inc. acquired a new position in Danaher during the second quarter worth $51,000. Finally, Western Pacific Wealth Management LP acquired a new position in Danaher during the first quarter worth $55,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 18.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 11.10% of the company’s stock.

Danaher Stock Down 0.9 %

DHR stock opened at $239.45 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The company has a market cap of $172.95 billion, a PE ratio of 45.70, a price-to-earnings-growth ratio of 4.44 and a beta of 0.85. Danaher Co. has a 52 week low of $204.15 and a 52 week high of $281.70. The business has a 50-day simple moving average of $263.42 and a 200 day simple moving average of $260.64.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.02 earnings per share. Sell-side analysts anticipate that Danaher Co. will post 7.51 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is 20.61%.

Analyst Ratings Changes

A number of brokerages recently weighed in on DHR. Leerink Partners boosted their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Stephens restated an “overweight” rating and set a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. UBS Group reduced their price objective on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Wells Fargo & Company began coverage on shares of Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. Finally, Robert W. Baird reduced their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.